C-X-C Chemokine Receptor Type 2 Market Report 2025

The C-X-C chemokine receptor type 2 market size has grown rapidly in recent years. It will grow from $1.24 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to the rising prevalence of diseases associated with C-X-C chemokine receptor type 2, increasing investment in research and development, growing incidence of chronic conditions, an expanding aging population, and a favorable regulatory environment.

The C-X-C chemokine receptor type 2 market size is expected to see rapid growth in the next few years. It will grow to $2.14 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to the increasing demand for targeted therapies, rising investments in anti-inflammatory drugs, growing focus on cancer immunotherapy, expanding collaborations and partnerships, and higher healthcare spending. Major trends during the forecast period include advancements in drug formulation technologies, innovations in biomarker discovery, progress in targeted therapies, and enhanced integration of digital health solutions.

The rising prevalence of inflammatory conditions is anticipated to drive the growth of the C-X-C chemokine receptor type 2 market in the coming years. Inflammatory conditions are medical disorders caused by the body's immune response, resulting in swelling, redness, heat, pain, and loss of function in affected tissues or organs. The increase in inflammatory conditions is largely attributed to rising environmental pollution, which triggers immune system responses and chronic inflammation. C-X-C Chemokine Receptor Type 2 (CXCR2) plays a key role in treating inflammatory conditions by precisely regulating immune cell migration and inflammatory responses. It minimizes off-target effects through small-molecule inhibitors and biologics that specifically modulate CXCR2 activity, enhancing treatment efficacy and patient outcomes. For example, in May 2024, the Centers for Disease Control and Prevention, a US government agency, reported that the prevalence of asthma among adults aged 18 and over in the United States rose from 8.7% in 2022 to 8.9% in 2023. Consequently, the growing prevalence of inflammatory conditions is driving the expansion of the C-X-C chemokine receptor type 2 market.

The increasing emphasis on targeted therapies is expected to further propel the growth of the C-X-C chemokine receptor type 2 market. Targeted therapies are treatments designed to specifically inhibit molecular abnormalities in cancer or other diseases, improving treatment precision while minimizing harm to healthy cells. This growing focus is mainly driven by advancements in precision medicine, which allow for personalized and more effective treatments based on individual genetic profiles. C-X-C chemokine receptor type 2 facilitates targeted therapies by guiding immune responses, supporting precise interventions for autoimmune and inflammatory diseases. It aids precision medicine through the development of small-molecule inhibitors and biologics that selectively modulate CXCR2 activity, enhancing therapeutic outcomes and reducing off-target effects. For instance, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, reported that the FDA approved 6 gene therapy products in 2023, up from 5 approvals in 2022. Therefore, the growing focus on targeted therapies is contributing to the expansion of the C-X-C chemokine receptor type 2 market.

In October 2022, Amgen Inc., a US-based biotechnology company, acquired ChemoCentryx Inc. for \$3.7 billion. Through this acquisition, Amgen aims to enhance its portfolio in inflammation and nephrology by accessing ChemoCentryx’s innovative small-molecule therapies targeting the chemoattractant system for rare and autoimmune diseases. ChemoCentryx Inc., a US-based biopharmaceutical company, is developing CXCR2-targeted therapies for autoimmune and inflammatory disorders.

Major players in the c-x-c chemokine receptor type 2 market are AstraZeneca plc, GSK plc, Eli Lilly and Company, Bio-Techne Corporation, Dompé Farmaceutici S.p.A., Miltenyi Biotec B.V. & Co. KG, Abcam plc, Selleck Chemicals LLC, Cell Signaling Technology Inc., RayBiotech Inc., Bethyl Laboratories Inc., Creative Biolabs Inc., TargetMol LLC, MedChemExpress LLC, BioCompare Inc., Boster Biological Technology Co. Ltd., TME Pharma GmbH, InvivoChem Ltd., Abbexa Ltd., Abiocode Inc.

North America was the largest region in the C-X-C chemokine receptor type 2 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in C-X-C chemokine receptor type 2 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the C-X-C chemokine receptor type 2 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

C-X-C chemokine receptor type 2 (CXCR2) is a G protein-coupled receptor predominantly found on neutrophils and other immune cells. It interacts with chemokines to mediate chemotaxis, directing immune cells to sites of infection or inflammation. Its primary function is to regulate inflammatory responses and coordinate immune cell recruitment, making it crucial for both host defense and pathological inflammation.

The primary product types targeting CXCR2 include antagonists, agonists, inhibitors, and other therapeutic agents. Antagonists block the receptor’s activity, preventing chemokine binding and thereby reducing inflammation and immune cell recruitment. Available drug formats include monoclonal antibodies, small molecule inhibitors, peptide-based therapies, and gene therapy products. These can be administered via intravenous, subcutaneous, oral, or topical routes. Applications span cancer therapy, autoimmune disorders, infectious diseases, and inflammatory conditions, with key end users including hospitals, research institutions, pharmaceutical companies, and contract research organizations.

The C-X-C chemokine receptor type 2 market research report is one of a series of new reports that provides C-X-C chemokine receptor type 2 market statistics, including the C-X-C chemokine receptor type 2 industry global market size, regional shares, competitors with the C-X-C chemokine receptor type 2 market share, detailed C-X-C chemokine receptor type 2 market segments, market trends, and opportunities, and any further data you may need to thrive in the C-X-C chemokine receptor type 2 industry. This C-X-C chemokine receptor type 2 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The C-X-C chemokine receptor type 2 market consists of sales of ribonucleic acid (RNA)-based therapeutics, cell-based therapies, biologic response modifiers, diagnostic imaging agents, companion diagnostics, and recombinant proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.